CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 57 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $16,383,500 | +31.6% | 350,000 | 0.0% | 1.29% | +26.2% |
Q4 2023 | $12,453,000 | +19.6% | 350,000 | 0.0% | 1.02% | -10.5% |
Q3 2023 | $10,409,000 | -4.4% | 350,000 | -32.3% | 1.14% | +133.1% |
Q3 2021 | $10,889,000 | -67.0% | 517,280 | -70.5% | 0.49% | -65.8% |
Q2 2021 | $33,032,000 | -2.4% | 1,752,346 | -20.9% | 1.43% | +20.3% |
Q1 2021 | $33,832,000 | +2.6% | 2,214,138 | -5.2% | 1.19% | -19.2% |
Q4 2020 | $32,959,000 | -7.1% | 2,335,889 | +3.2% | 1.47% | -28.2% |
Q3 2020 | $35,473,000 | -12.6% | 2,263,770 | -2.3% | 2.05% | -29.6% |
Q2 2020 | $40,587,000 | -16.9% | 2,316,628 | -30.2% | 2.91% | -34.2% |
Q1 2020 | $48,816,000 | -42.1% | 3,320,801 | -1.6% | 4.42% | -44.1% |
Q2 2019 | $84,379,000 | +9.8% | 3,375,169 | 0.0% | 7.91% | +3.2% |
Q1 2019 | $76,819,000 | -32.5% | 3,375,169 | -11.0% | 7.66% | -47.3% |
Q4 2018 | $113,727,000 | +4.7% | 3,792,169 | 0.0% | 14.52% | +32.6% |
Q3 2018 | $108,646,000 | – | 3,792,169 | – | 10.95% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |